Use of 2940-nm Erbium-Yag Fractional Laser for treating the skin texture changes in stabilized Parry Romberg Syndrome

Ghorbel, H. Hammami; Lacour, Jean‐Philippe; Passeron, Thierry

doi:10.1684/ejd.2013.2217

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After each session, marked improvement of the texture, color, and pliability was noted. Significant cosmetic improvement was maintained for 2 years after the last treatment [ 60 ].…”

Section: Resultsmentioning

confidence: 99%

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Szczepanik-Kułak

Michalska-Jakubus

Krasowska

2021

JCM

View full text Add to dashboard Cite

Morphea, also known as localized scleroderma (LoS), comprises a set of autoimmune sclerotic skin diseases. It is characterized by inflammation and limited thickening and induration of the skin; however, in some cases, deeper tissues might also be involved. Although morphea is not considered a life-threatening disease, the apparent cosmetic disfigurement, functional or psychosocial impairment affects multiple fields of patients’ quality of life. Therapy for LoS is often unsatisfactory with numerous treatments that have only limited effectiveness or considerable side effects. Due to the advances in the application of lasers and their possible beneficial effects, the aim of this study is to review the reported usage of laser in morphea. We present a systematic review of available literature, performed with MEDLINE, Cinahl, Central, Scopus, Web of Science, and Google Scholar databases. We identified a total of twenty relevant studies (MEDLINE n = 10, Cinahl n = 1, Central n = 0, Scopus n = 2, Web of Science n = 5, Google Scholar n = 2) using laser therapy for LoS. Eight studies were focused on the use of PDL, six on fractional lasers (CO2 and Er:YAG), four on excimer, and two on either alexandrite or Nd:YAG.

show abstract

“…After each session, marked improvement of the texture, color, and pliability was noted. Significant cosmetic improvement was maintained for 2 years after the last treatment [ 60 ].…”

Section: Resultsmentioning

confidence: 99%

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Szczepanik-Kułak

Michalska-Jakubus

Krasowska

2021

JCM

View full text Add to dashboard Cite

show abstract

“…Previous studies have documented marked softening and improved dyschromia after laser treatment. 13,14 Shalaby et al 13 compared the efficacy of CO 2 laser treatment versus low-dose UVA-1 therapy, indicating fractional CO 2 laser improved collagen deposition in morphea patients based on the clinical and histopathologic assessment, which was superior to low-dose UVA-1 phototherapy.…”

Section: Discussionmentioning

confidence: 99%

“…13 A case report revealed potential fractional erbium:yttriumaluminum-garnet (Er:YAG) laser conducive to the improvement of morphea. 14 Compared with fractional CO 2 laser, fractional Er:YAG laser delivers a powerful wavelength of 2940 nm that closely approximates the absorption of light peak of water. As the skin consists of 60%-80% water, fractional Er:YAG laser results in effective ablation of target area with minimal tissue ablation and thermal damage to its surrounding tissue, producing less erythema, and adverse reaction.…”

Section: Backg Rou N Dmentioning

confidence: 99%

Fractional erbium:yttrium aluminum garnet laser in the treatment of morphea mouse model

Guo

Huang

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

ObjectiveTo assess the efficiency and the mechanism of fractional erbium:yttrium aluminum garnet (Er:YAG) laser for the treatment of morphea in mouse model.BackgroundMorphea is a rare autoimmune disease characterized by excessive collagen deposition in skin. Fractional Er:YAG laser treatment is a promising treatment to improve morphea, despite limited studies about the therapeutic effect and underlying mechanism.MethodsThe mouse model of morphea was established by subcutaneously injecting with bleomycin (BLM). A total of 24 mice received fractional Er:YAG laser treatment once a week for 4 weeks. Objective measurement employed was ultrasonic imaging to measure dermal thickness. Subjective measures included scoring according to the adjusted Localized morphea Cutaneous Assessment Tool (LoSCAT); hematoxylin and eosin (H&E) staining to evaluate the histological grade of fibrosis; and quantitative morphometric studies to determine the expression of transforming growth factor‐β1 (TGF‐β1) and matrix metalloproteinase‐1 (MMP1) by immunohistochemistry.ResultsIn this self‐controlled study, fractional Er:YAG laser treatment significantly ameliorate the severity of morphea, including lower clinical score (p < 0.01), decreased dermal thickness (p < 0.001), declined histological grade of fibrosis (p < 0.001), increased MMP1 (p < 0.001), and reduced TGF‐β1 (p < 0.01) expression.ConclusionsWe found that fractional Er:YAG laser treatment of morphea has good clinical, ultrasonic, and histopathologic efficacy, which may be a promising treatment in the future.

show abstract

“…The literature provides reports on the correction of aesthetic defects using laser and light-based therapy, injectables, and surgical interventions [12]. Promising results from treatment with a fractional ablative carbon dioxide laser [13][14][15][16], pulsed dye laser (PDL) [17][18][19][20][21][22][23][24], excimer laser [25][26][27][28], Er:YAG fractional laser [29,30], Q-switched alexandrite laser [31], and long-pulsed Nd:YAG laser associated with pulsed light [32] have been presented.…”

Section: Introductionmentioning

confidence: 99%

Fractional Ablative Carbon Dioxide Lasers for the Treatment of Morphea: A Case Series and Literature Review

Klimek

Placek

Owczarczyk‐Saczonek

2022

IJERPH

View full text Add to dashboard Cite

Morphea is an inflammatory, immune-mediated disease of unknown aetiology. It is characterised by excessive collagen deposition, which leads to the hardening of the dermis and subcutaneous tissues. The disease is associated with cosmetic and functional impairment, which can affect the patients’ quality of life. Fractional ablative lasers (FALs) are currently used for the treatment of many skin diseases that are connected to tissue fibrosis due to the low risk of side effects and their great effectiveness. This study aimed to improve the aesthetic defects that are caused by morphea lesions and assess the efficacy and safety of FAL use in this indication. We also reviewed the literature on the subject. We present four women with biopsy-proven morphea, manifesting as hyperpigmented plaques and patches. One of the patients additionally had morphea-related knee joint contracture. Four fractional CO2 laser sessions, separated by one-month intervals, were performed and produced significant improvements in dyspigmentation and induration. An improved elasticity and a decrease in dermal thickness were also obtained, as proven by measurements using DermaLab Combo. No severe adverse effects occurred. Based on these cases presented by the authors, fractional CO2 lasers appear to be an effective, well-tolerated, and safe therapeutic option for patients suffering from morphea.

show abstract

Use of 2940-nm Erbium-Yag Fractional Laser for treating the skin texture changes in stabilized Parry Romberg Syndrome

Cited by 6 publications

References 0 publications

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Fractional erbium:yttrium aluminum garnet laser in the treatment of morphea mouse model

Fractional Ablative Carbon Dioxide Lasers for the Treatment of Morphea: A Case Series and Literature Review

Contact Info

Product

Resources

About